Ascendis Pharma's navepegritide wins CHMP backing for achondroplasia
Ascendis Pharma has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for navepegritide, its once-weekly prodrug of C-type natriuretic peptide (CNP), in the treatment of achondroplasia in children aged two and older whose epiphyses remain open. The European Commission is expected to issue a final marketing authorisation decision in Q4 2026, and Ascendis has said it anticipates launching the product in Germany under the brand name YUVIWEL in the first quarter of 2027.
The CHMP opinion was based on a package that included data from three randomised, double-blind, placebo-controlled trials and up to three years of open-label extension data. Pivotal results from the ApproaCH trial were published in JAMA Pediatrics earlier this year. Navepegritide was designated as an orphan medicine during its development, and the EMA will separately assess whether that designation can be maintained following authorisation.
Regulatory read-across
The positive EU opinion follows FDA approval of YUVIWEL in February 2026, making navepegritide one of the few treatments for achondroplasia to have secured regulatory backing on both sides of the Atlantic within a single calendar year. That transatlantic alignment is significant: achondroplasia is estimated to affect around 250,000 people worldwide, and the rare-disease designation in both jurisdictions reflects the limited treatment options historically available to this population.
Jan Mikkelsen, president and chief executive of Ascendis Pharma, said the positive opinion reflected "the unique profile of TransCon CNP" and that the product remained a foundational asset in the company's growth disorder portfolio, positioned to support its Vision 2030 objectives.
Market context
Navepegritide enters a nascent but increasingly competitive rare skeletal-dysplasia market. BioMarin Pharmaceutical's vosoritide (Voxzogo), a once-daily CNP analogue, received EMA approval in 2021 and FDA approval in 2021, and has been building commercial presence in both markets. The key differentiator Ascendis is promoting is continuous systemic CNP exposure over a weekly dosing interval, in contrast to the daily administration required by vosoritide. Whether that dosing convenience translates into meaningful patient or prescriber preference will be tested commercially from Q1 2027 onwards.
Achondroplasia, caused by a variant in the fibroblast growth factor receptor 3 (FGFR3) gene, produces a broader burden of disease than skeletal dysplasia alone. Neurological, cardiorespiratory, and muscular complications are common across life stages, and the indication's orphan status in both the US and EU underscores the regulatory priority given to this population. Health technology assessment bodies across EU member states, particularly in markets beyond Germany, will scrutinise the comparative clinical data against vosoritide when determining reimbursement conditions.
Ascendis is headquartered in Copenhagen and trades on NASDAQ under the ticker ASND. The company has built its pipeline around its proprietary TransCon platform, which uses prodrug chemistry to modulate the release profile of active molecules, and navepegritide represents one of its most advanced commercial assets alongside its approved growth hormone therapy. Investors and analysts will be watching closely for early German uptake data as a proxy for broader EU commercial traction ahead of subsequent country launches.